Seer, Inc.
NASDAQ:SEER · NASDAQ Global Select
+$0.01 today
Vol 0.08M · Avg 0.32M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$73.6M +15.0% | -$86.6M -0.4% | -$86.3M +7.2% | -$93.0M -30.6% | -$71.2M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $7.2M +17.3% | $6.2M +10.7% | $5.6M +41.5% | $3.9M +54.1% | $2.6M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $1.2M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $15.4M -45.4% | $28.2M -18.1% | $34.4M +2.2% | $33.7M +29.9% | $25.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$579.0K -302.1% | -$144.0K +94.7% | -$2.7M +61.6% | -$7.1M -20.9% | -$5.9M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $277.0K -43.1% | $487.0K +61.3% | $302.0K +110.5% | -$2.9M -15.2% | -$2.5M | $592.6M | $1.3B | $626.2M |
| Inventory | -$2.9M -8.7% | -$2.7M -37.0% | -$1.9M -22.5% | -$1.6M +55.8% | -$3.6M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $1.1M -68.3% | $3.4M +439.9% | -$987.0K +36.4% | -$1.6M -196.9% | $1.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $983.0K +174.6% | -$1.3M -1348.4% | -$91.0K +91.5% | -$1.1M +22.2% | -$1.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $7.1M +13.1% | $6.3M +162.1% | -$10.1M -706.0% | $1.7M +65.3% | $1.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$44.4M +3.6% | -$46.1M +21.9% | -$59.1M +2.8% | -$60.8M -31.1% | -$46.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.8M +49.9% | -$3.6M +51.0% | -$7.3M +28.8% | -$10.3M -48.3% | -$6.9M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 -100.0% | $164.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$173.2M +36.6% | -$272.9M +32.3% | -$403.1M -10.1% | -$366.3M -30.8% | -$280.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $237.8M -30.5% | $342.0M -23.7% | $448.3M +76.7% | $253.6M +118.7% | $116.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$1.3M -478.7% | $343.0K | $0 -100.0% | $170.0K +100.1% | -$164.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $61.5M -6.5% | $65.9M +73.7% | $37.9M +130.9% | -$122.7M +28.2% | -$170.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $458.0K | $0 | $0 | $0 -100.0% | $103.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$10.2M +13.7% | -$11.8M -90792.3% | -$13.0K +35.0% | -$20.0K +42.9% | -$35.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$827.0K -357.6% | $321.0K -31.0% | $465.0K -88.1% | $3.9M -71.5% | $13.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$10.6M +8.1% | -$11.5M -2643.1% | $452.0K -88.4% | $3.9M -96.7% | $116.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $6.5M -20.9% | $8.3M +139.9% | -$20.7M +88.5% | -$179.6M -78.5% | -$100.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$46.2M +6.9% | -$49.7M +25.1% | -$66.4M +6.6% | -$71.0M -33.4% | -$53.3M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.40B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.65B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.48B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.18B
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$943.77M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$894.39M
Sana Biotechnology, Inc.
NASDAQ:SANA
$869.66M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$335.86M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$294.24M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$242.78M
Shattuck Labs, Inc.
NASDAQ:STTK
$231.97M
Quantum-Si incorporated
NASDAQ:QSI
$196.42M
Nkarta, Inc.
NASDAQ:NKTX
$194.67M
Molecular Partners AG
NASDAQ:MOLN
$147.61M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$136.19M
PepGen Inc.
NASDAQ:PEPG
$124.28M
MediciNova, Inc.
NASDAQ:MNOV
$65.22M
Generation Bio Co.
GBIO
$35.98M
Anebulo Pharmaceuticals, Inc.
ANEB
$17.23M
HCW Biologics Inc.
HCWB
$2.21M
SEC Filings
Recent regulatory filings
No filings found.
Does SEER generate free cash flow?
Seer, Inc. (SEER) generated -$46,245,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does SEER produce?
Operating cash flow was -$44,448,000.00, before capital expenditures of $1.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.